# Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

> **NCT01218802** · PHASE2 · COMPLETED · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 147 (actual)

## Conditions studied

- HIV Infections
- Heart Disease

## Interventions

- **DRUG:** Rosuvastatin 10 mg. daily for 96 weeks
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01218802
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2016-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218802, "Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01218802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*